Board Member Artur Aira is taking the position as Bioprinting Business Area Manager

Report this content

Artur Aira, who holds a master’s degree in medical technology engineering and an MBA, is leaving the CELLINK Board of Directors for an operational role as Business Area Manager for the bioprinting business unit.

Artur has a wealth of experience within the life sciences industry, has served as CEO Abigo medical, Executive Vice President at AddLife, and has held various leadership roles at Organon Teknika, bioMerieux and AddTech Life Science. With over 30 years’ experience, he is an authority on setting up organizations in the pharmaceutical and diagnostics industries to achieve impressive growth rates.

The appointment of Artur as the Business Area Manager for bioprinting is part of CELLINK’s effort to strengthen its position as a global leader in the bioprinting landscape. By coupling high-quality biomaterials with affordable hardware solutions, CELLINK seeks to develop automated workflows and elevate 3D cell culture in cell and molecular biology research. Artur will start operationally the 1st of January 2021 and are today stepping down from the Board of directors.              

Erik Gatenholm, CEO, CELLINK Group:

“It is an honor to appoint Artur as the Bioprinting Business Area Manager. We look forward to his leadership and strategic outlook to support the growth of CELLINK within the bioprinting area and his help with our overall vision to create the future of medicine.”

Artur Aira, BAM, CELLINK

“I have been more than 2 years at the board of Cellink and have been part of the enormous success of the company. I’m very happy, motivated and excited to be operational and part of the team that creates the future of medicine.”

CELLINK will call for the nomination committee to recommend the appointment of a new member of the board of directors, after which the candidate will be presented in further detail in connection with the convening notice to the extraordinary general meeting expected to be held in November

For further information, please contact:

Erik Gatenholm, CEO                                                     Gusten Danielsson, CFO                             
Phone (Sweden): +46 73 267 00 00                                Phone (Sweden): +46 70 991 86 04      
Phone (US): +1 (650) 515 5566                                       Phone (US): +1 (857) 332 2138
Email:                                                     Email:                               

This information was submitted for publication, through the agency of the contact persons set out above, on October 2, 2020. 17:00 CET.


Founded in 2016, CELLINK is a global life-science company that provides technologies, products and services to create, understand, and master cell and molecular biology. With a focus on the application areas of bioprinting, analysis, and liquid handling and bioprocessing, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,000 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 55 countries, and have been cited in more than 150 publications. CELLINK is creating the future of medicine.

Visit to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.


Documents & Links